News of Note—Emergent’s new CEO, Valneva’s chikungunya vaccine and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Emergent BioSolutions announced that its CEO since 2012, Daniel J. Abdun-Nabi, will retire and be replaced by Robert G. Kramer, Sr., the company’s current president and COO, effective Apr. 1, 2019. Release

> Valneva reported positive phase 1 interim results for its chikungunya vaccine candidate, VLA1553, showing a single vaccination achieved a 100% seroconversion rate at Day 28. The news came as the company announced plans to delist from the Vienna Stock Exchange to focus trading on Euronext Paris. Release | Release

> Walter Ricciardi, president of Italy’s National Institute of Health, has resigned, accusing the League and Five Star Movement-led government’s antivaccine stance and other “unfounded” health claims. The BMJ article

> The Coalition for Epidemic Preparedness Innovations is making $48 million of funding available to support development of vaccines against Rift Valley fever and chikungunya. Release

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.